MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval

The US Medicare Payment Advisory Commission’s initial list of ideas to overhaul payment for drugs in the physician-administered Part B setting includes applying cost-effectiveness benchmarks for new drugs and biologics approved via the Accelerated Approval pathway.

At its 7 October meeting, MedPAC began consideration of proposals to address the “high prices” of drugs covered under Part B. The MedPAC staff offered three potential changes as a...